Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment

L H Marbjerg; B J Holzknecht; R Dargis; R B Dessau; X C Nielsen; J J Christensen

doi:10.1016/j.diagmicrobio.2020.115028

Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment

L H Marbjerg, B J Holzknecht, R Dargis, R B Dessau, X C Nielsen, J J Christensen

Research output: Contribution to journal › Journal article › Research › peer-review

4 Citations (Scopus)

Abstract

The aim of this study was to evaluate the clinical value of partial 16S/18S rRNA gene sequencing with the commercial kit Micro-Dx™ used with the SelectNA™plus instrument on culture-negative samples. A retrospective study of microbiological and clinical data from a 2.5-year period was performed. Assessment of the clinical relevance of the 16S/18S rRNA gene sequencing results was based on evaluation of the results in the clinical context and changes in antimicrobial therapy. Included were 529 samples from 223 patients, representing 251 episodes. In 191 samples (36.1%), bacterial/fungal DNA was detected. Positive results were judged clinically relevant in 79 (31.5%) episodes. Antimicrobial treatment was adjusted according to the 16S/18S rRNA gene sequence analysis result in 42 (16.7%) episodes. The results from 16S/18S rRNA gene sequence analysis were highly clinically relevant. These findings support the use of this analysis in a routine setting.

Original language	English
Article number	115028
Journal	Diagnostic Microbiology and Infectious Disease
Volume	97
Issue number	2
Number of pages	5
ISSN	0732-8893
DOIs	https://doi.org/10.1016/j.diagmicrobio.2020.115028
Publication status	Published - 2020

Access to Document

10.1016/j.diagmicrobio.2020.115028

Cite this

Marbjerg, L. H., Holzknecht, B. J., Dargis, R., Dessau, R. B., Nielsen, X. C., & Christensen, J. J. (2020). Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment. Diagnostic Microbiology and Infectious Disease, 97(2), [115028]. https://doi.org/10.1016/j.diagmicrobio.2020.115028

Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites : diagnostic value and implications for antimicrobial treatment. / Marbjerg, L H; Holzknecht, B J; Dargis, R; Dessau, R B; Nielsen, X C; Christensen, J J.

In: Diagnostic Microbiology and Infectious Disease, Vol. 97, No. 2, 115028, 2020.

Research output: Contribution to journal › Journal article › Research › peer-review

Marbjerg, LH, Holzknecht, BJ, Dargis, R, Dessau, RB, Nielsen, XC & Christensen, JJ 2020, 'Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment', Diagnostic Microbiology and Infectious Disease, vol. 97, no. 2, 115028. https://doi.org/10.1016/j.diagmicrobio.2020.115028

Marbjerg LH, Holzknecht BJ, Dargis R, Dessau RB, Nielsen XC, Christensen JJ. Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment. Diagnostic Microbiology and Infectious Disease. 2020;97(2). 115028. https://doi.org/10.1016/j.diagmicrobio.2020.115028

@article{9a375b6773524b6d91438d36e15e01fc,

title = "Commercial bacterial and fungal broad-range PCR (Micro-Dx{\texttrademark}) used on culture-negative specimens from normally sterile sites: diagnostic value and implications for antimicrobial treatment",

abstract = "The aim of this study was to evaluate the clinical value of partial 16S/18S rRNA gene sequencing with the commercial kit Micro-Dx{\texttrademark} used with the SelectNA{\texttrademark}plus instrument on culture-negative samples. A retrospective study of microbiological and clinical data from a 2.5-year period was performed. Assessment of the clinical relevance of the 16S/18S rRNA gene sequencing results was based on evaluation of the results in the clinical context and changes in antimicrobial therapy. Included were 529 samples from 223 patients, representing 251 episodes. In 191 samples (36.1%), bacterial/fungal DNA was detected. Positive results were judged clinically relevant in 79 (31.5%) episodes. Antimicrobial treatment was adjusted according to the 16S/18S rRNA gene sequence analysis result in 42 (16.7%) episodes. The results from 16S/18S rRNA gene sequence analysis were highly clinically relevant. These findings support the use of this analysis in a routine setting.",

author = "Marbjerg, {L H} and Holzknecht, {B J} and R Dargis and Dessau, {R B} and Nielsen, {X C} and Christensen, {J J}",

year = "2020",

doi = "10.1016/j.diagmicrobio.2020.115028",

language = "English",

volume = "97",

journal = "Diagnostic Microbiology and Infectious Disease",

issn = "0732-8893",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Commercial bacterial and fungal broad-range PCR (Micro-Dx™) used on culture-negative specimens from normally sterile sites

T2 - diagnostic value and implications for antimicrobial treatment

AU - Marbjerg, L H

AU - Holzknecht, B J

AU - Dargis, R

AU - Dessau, R B

AU - Nielsen, X C

AU - Christensen, J J

PY - 2020

Y1 - 2020

N2 - The aim of this study was to evaluate the clinical value of partial 16S/18S rRNA gene sequencing with the commercial kit Micro-Dx™ used with the SelectNA™plus instrument on culture-negative samples. A retrospective study of microbiological and clinical data from a 2.5-year period was performed. Assessment of the clinical relevance of the 16S/18S rRNA gene sequencing results was based on evaluation of the results in the clinical context and changes in antimicrobial therapy. Included were 529 samples from 223 patients, representing 251 episodes. In 191 samples (36.1%), bacterial/fungal DNA was detected. Positive results were judged clinically relevant in 79 (31.5%) episodes. Antimicrobial treatment was adjusted according to the 16S/18S rRNA gene sequence analysis result in 42 (16.7%) episodes. The results from 16S/18S rRNA gene sequence analysis were highly clinically relevant. These findings support the use of this analysis in a routine setting.

AB - The aim of this study was to evaluate the clinical value of partial 16S/18S rRNA gene sequencing with the commercial kit Micro-Dx™ used with the SelectNA™plus instrument on culture-negative samples. A retrospective study of microbiological and clinical data from a 2.5-year period was performed. Assessment of the clinical relevance of the 16S/18S rRNA gene sequencing results was based on evaluation of the results in the clinical context and changes in antimicrobial therapy. Included were 529 samples from 223 patients, representing 251 episodes. In 191 samples (36.1%), bacterial/fungal DNA was detected. Positive results were judged clinically relevant in 79 (31.5%) episodes. Antimicrobial treatment was adjusted according to the 16S/18S rRNA gene sequence analysis result in 42 (16.7%) episodes. The results from 16S/18S rRNA gene sequence analysis were highly clinically relevant. These findings support the use of this analysis in a routine setting.

U2 - 10.1016/j.diagmicrobio.2020.115028

DO - 10.1016/j.diagmicrobio.2020.115028

M3 - Journal article

C2 - 32278620

VL - 97

JO - Diagnostic Microbiology and Infectious Disease

JF - Diagnostic Microbiology and Infectious Disease

SN - 0732-8893

IS - 2

M1 - 115028

ER -